ImmunityBio
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 628
- Market Cap
- $2.9B
- Website
- http://www.immunitybio.com
- Introduction
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong ...
HCW9218 for Advanced Pancreatic Cancer
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05304936
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
- Conditions
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04927884
- Locations
- 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04898543
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT04845191
COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT04843722
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT04732468
- Locations
- 🇺🇸
Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT04710303
- Locations
- 🇿🇦
Khayelitsha Clinical Research Site, Khayelitsha, South Africa
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04591717
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Chan Soon - Shiong Institute for Medicine, El Segundo, California, United States
Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04397796
- Locations
- 🇺🇸
St. Francis Medical Center, Lynwood, California, United States
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04390399
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag memorial Presbyterian Hospital, Newport Beach, California, United States